ADVANCED MEDICAL ISOTOPE CORPORATION (OTCMKTS:ADMD) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
On August 1, 2017, Advanced Medical Isotope Corporation (the “Company”) held a shareholder update webcast. In connection with the webcast, the Company used presentation materials, furnished as Exhibit 99.1 hereto, which is incorporated herein by reference.
In accordance with General Instruction B.2 for Form 8-K, the information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
See Exhibit Index.
ADVANCED MEDICAL ISOTOPE Corp Exhibit…To view the full exhibit click here
About ADVANCED MEDICAL ISOTOPE CORPORATION (OTCMKTS:ADMD)
Advanced Medical Isotope Corporation, formerly Savage Mountain Sports Corporation, is a radiation oncology focused medical device company. The Company is engaged in the development of yttrium-90 (Y-90)-based brachytherapy devices for the treatment of non-resectable tumors. Brachytherapy uses radiation to manage cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company’s lead product is the Y-90 RadioGel device. The Company is engaged in the development of its brachytherapy products, which includes Y-90 RadioGel device, Y-90 Fast-Resorbable Polymer Seeds and Y-90 Polymer Topical Paste. Y-90 RadioGel device combines Y-90 particles with a polymer carrier that is injected into the tumor. Y-90 Fast-Resorbable Polymer Seeds contains Y-90 within a polymer seed, as opposed to metal or glass. Y-90 Polymer Topical Paste is designed to be applied to tissue surfaces after surgical tumor removals to treat residual tumor cells.
